3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV.

Due to the high polymorphism of natural hepatitis C virus (HCV) variants, existing recombinant HCV replication models have failed to be effective in developing effective anti-HCV agents. In the current study, we describe an in vitro system that supports the infection and replication of natural HCV from patient blood using an immortalized primary human hepatocyte cell line cultured in a three-dimensional (3D) culture system. Comparison of the gene expression profile of cells cultured in the 3D system to those cultured in the existing 2D system demonstrated an up-regulation of several genes activated by peroxisome proliferator-activated receptor alpha (PPARalpha) signaling. Furthermore, using PPARalpha agonists and antagonists, we also analyzed the effect of PPARalpha signaling on the modulation of HCV replication using this system. The 3D in vitro system described in this study provides significant insight into the search for novel anti-HCV strategies that are specific to various strains of HCV.

[1]  P. Tontonoz,et al.  Liver X receptors are regulators of adipocyte gene expression but not differentiation: identification of apoD as a direct target. , 2004, Journal of lipid research.

[2]  Ralf Bartenschlager,et al.  Production of infectious hepatitis C virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral RNA of genotype 1b. , 2006, Virology.

[3]  R. Dickson.  Clinical manifestations of hepatitis C. , 1997, Clinics in liver disease.

[4]  J. Kehrer,et al.  Mechanisms of N-acetylcysteine-driven enhancement of MK886-induced apoptosis , 2006, Cell Biology and Toxicology.

[5]  G. Andrei.  Three-dimensional culture models for human viral diseases and antiviral drug development. , 2006, Antiviral research.

[6]  D. Jump,et al.  Fatty acid regulation of hepatic gene transcription. , 2005, The Journal of nutrition.

[7]  K. Shimotohno,et al.  Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. , 2006, Biochemical and biophysical research communications.

[8]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[9]  E Jenny Heathcote,et al.  Antiviral therapy: chronic hepatitis C , 2007, Journal of viral hepatitis.

[10]  D. Crabb,et al.  Alcohol and lipid metabolism , 2006, Journal of gastroenterology and hepatology.

[11]  Hussein H. Aly,et al.  Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. , 2007, Journal of hepatology.

[12]  Z. Younossi,et al.  The effects of HCV infection and management on health‐related quality of life , 2007, Hepatology.

[13]  C. Rice,et al.  Efficient initiation of HCV RNA replication in cell culture. , 2000, Science.

[14]  Hussein H. Aly,et al.  In Vitro Infection of Immortalized Primary Hepatocytes by HCV Genotype 4a and Inhibition of Virus Replication by Cyclosporin , 2007, Microbiology and immunology.

[15]  I. Berget,et al.  Differential gene expression of fatty acid binding proteins during porcine adipogenesis. , 2008, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[16]  Sui Huang,et al.  PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.

[17]  K. Griffin,et al.  Peroxisome proliferator activated receptor-alpha expression in human liver. , 1998, Molecular pharmacology.

[18]  M. Holness,et al.  Fasting-induced increases in aquaporin 7 and adipose triglyceride lipase mRNA expression in adipose tissue are attenuated by peroxisome proliferator-activated receptor α deficiency , 2007, International Journal of Obesity.

[19]  K. Shimotohno,et al.  Enhancement of internal ribosome entry site-mediated translation and replication of hepatitis C virus by PD98059. , 2005, Virology.

[20]  X. Xie,et al.  Peroxisome Proliferator-Activated Receptor α Antagonism Inhibits Hepatitis C Virus Replication , 2006 .